Observing blood-thinning treatments in people with multiple myeloma
Studies which blood thinners prevent clots in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Key facts
- Where
- Roma, ItalySee the site
Where in Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS UOC Servizio e DH di EmatologiaRoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Trial code
- NCT06028087
- Record updated
- 14 March 2025
- Original description
The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous thromboembolism (VTE).Read full original descriptionShow less
Real-World Mapping Antithrombotic Regimens in Multiple Myeloma Patients on Treatment (The MAMMOTH Study of the GIMEMA Working Party on Hemostasis and Thrombosis)
The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous thromboembolism (VTE).
Inclusion: Age equal to or greater than 18 years of age; New diagnosis of symptomatic MM according to the CRAB or the SLIM criteria of the International Myeloma Working Group; First active treatment for MM started after recruitment in the study; Signed informed consent.
Exclusion: Patients having had thrombosis within 6 months before diagnosis of MM; Patients with need of combined antithrombotic regimens (i.e. VKA or DOAC or LMWK and one or two antiplatelet drugs); Ongoing first active treatment for MM initiated before the starting of the study.